Lundbeck Falls After Alzheimer’s Drug Fails in Late-Stage Study

H. Lundbeck A/S dropped the most in almost four years after its experimental Alzheimer’s drug failed to meet targets in a final-stage patient trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.